Vitamins in cholestasis

Newborn use only

Alert	The dose recomm					-	opinion.				
	International units (IU) are labelled as units in this formulary.										
	Bio-Logical Vitamin A oral solution and OsteVit D oral liquid contains sodium benzoate. Avoid exposure of >99mg/kg/day in neonates.							exposure of			
La di a at a a											
Indication	Neonatal cholestasis Vitamin A: Fat soluble vitamin required for vision, growth and bone development, immune function and										
Action	Vitamin A: Fat soluble vitamin required for vision maintenance of epithelial cells particularly in the							•	-	inction and	
	Vitamin D: Regula	-	-	-							
	Vitamin E: Antiox	_		-	-					conherol	
			-							copherol.	
Drug type	Fat and water sol		s the activation of blood coagulation Factors II, VII, IX and X in the liver. le vitamins								
Trade name	Pentavite Infant I										
aac name	Bio-Logical Vitam	•	•								
	Ostelin Vitamin-D										
	Pretorius Micel-E		•								
	Konakion MM Pa		· ·								
Presentation	Pentavite Infant -			ntains 1287 ur	nits of v	itamin /	A and 400	units	of vitamin D.		
	Bio-Logical Vitam										
	Ostelin Vitamin -	D (Vita	amin D3) ora	l liquid – 0.5 ı	nL con	tains 10	00 units o	f vitai	min D.		
	Pretorius Micel-E	oral li	iquid – 0.1 m	L contains 15	.6 unit	s of vita	min E.				
	Konakion MM Pa	ediatr	ic – 0.2 mL c	ontains 2 mg	vitamir	ո K ₁ .					
Dose	Suggested starting	ng regi	imen ⁽¹⁻⁴⁾								
		V	itamin A	Vitamir	n D Vita		min E	nin E Vitamin K₁		ı K ₁	
	Dose range	3000	0-5000 units	1000-2000	0 units 15		0 units 2 m		ng twice a week up to 2 mg		
	per day (not			(25-50 µ) μg)				daily		
	per kg)										
	Medical office	Medical officers to prescribe the following Dose Range									
	I Wiedical Office	13 10 1	prescribe the following		Dose Range					Mit a continue M	
	Vitamins		Oral preparation		Vitamin A (units)		Vitamin D (units)		Vitamin E (units)	Vitamin K₁ (mg)	
	Vitaliilis		Oral pro	paration	,ω.		(annex	••	(units)	(6/	
			Dose (mL) and								
			-	uency							
	Pentavite Infant				1287	7-2574	400-800		-	-	
							(10-20 µg)				
	Bio-Logical Vitamin		0.1 mL daily*		25	500	-		_	-	
	A solution			-							
	Ostelin Vitamin-	-D 0.5 mL		_daily*	daily*		- 1000		-	-	
	oral liquid 1000					(25		g)			
	units/0.5 mL#										
	Pretorius Micel-	·E	0.1-0.2 mL daily*		-		-		15-30	- 7	
	liquid										
				o a week to		-	-		- 2 mg tv		
	Konakion MM									a week to 2	
	Konakion MM Paediatric			aily							
				nily						mg daily	
					3787	-5074	1400-1		15-30	mg daily 2 mg twice	
				nily	3787	-5074	1400-13 (35-45		15-30	mg daily 2 mg twice a week to 2	
	Paediatric		da	Total					15-30	mg daily 2 mg twice	
	Paediatric *The daily dose m	-	da e administera	Total ed in two divi	ded dos	ses.	(35-45	μg)		mg daily 2 mg twice a week to 2 mg daily	
	*The daily dose n	D is th	e administere e preferred	Total ed in two divioliquid because	ded dos	ses.	(35-45	μg)		mg daily 2 mg twice a week to 2 mg daily	
Dose adjustment	Paediatric *The daily dose m	D is th	e administere e preferred	Total ed in two divioliquid because	ded dos	ses.	(35-45	μg)		mg daily 2 mg twice a week to 2 mg daily	

ANMF consensus group JHCH_NICU_19.179

Vitamins in cholestasis

Newborn use only

Maximum dose						
Total cumulative						
dose						
Route	Oral					
Preparation	No preparation is r	•				
Administration	Administer undilute					
Monitoring	Check serum levels of vitamins A, D, E and PT/INR in 1-3 monthly. May need more frequent monitoring in the initial weeks of therapy.					
Contraindications	Hypersensitivity to vitamin A, D, E, K or any component of the formulations. Hypervitaminosis of A, E and/or D.					
Precautions		•				
Drug interactions	May increase effects of anticoagulant and antiplatelet agents					
Adverse reactions	Hypervitaminosis A: Irritability, lethargy, vomiting, bulging fontanelle.					
	Hypervitaminosis D: Hypercalcaemia, nephrocalcinosis.					
			thy, sepsis, necrotising en	terocolitis.		
Compatibility	Not applicable	<u> </u>	7, 1			
Incompatibility	Not applicable Not applicable					
Stability	Pentavite Infant liquid: Use within 9 weeks after opening.					
,	The state of the s		roduct information.			
Storage	All products: Store	•				
	Pentavite Infant liq		_			
Excipients			arin, pineapple flavour.			
•	Bio-Logical Vitamin					
	_		te, caramel flavour.			
			ım sorbate and soy bean ı	products.		
			acid, lecithin, sodium hy		icid.	
Special comments	Vitamin E 1 unit = 0	· ·	·			
•	1 mg of retinyl palr					
Evidence	Background					
	There is a high prev	alence of vitamin	deficiency in neonatal ch	olestasis, with one stud	dy reporting rates of	
	-		in D (61%), vitamin A (29%			
			equently in all cholestatic		_	
			fractures and rickets (vita			
	and blindness (vitamin A deficiency), and neurologic and muscular abnormalities (vitamin E deficiency). (5)					
	Efficacy				(4.4)	
			is in neonatal cholestasis			
		•	upplementation of vitami	ns D, A, E, or K, along v	with the preferred	
	multivitamin formu					
			ble vitamins are as follow		T	
	Author	Vitamin A	Vitamin D	Vitamin E	Vitamin K	
	Feldman ⁽⁴⁾	3000-10000	800-5000 IU/day OR	Maintain serum	2.5- 5 mg twice a	
		U/day	1,25 OH ₂ D3: 0.05-0.2	targets. No dose	week to every day	
			μg/kg/day	recommendations.		
	Italian society (1)	5000-25000	800-5000 U/day	15-25 U/kg/day	2.5-5 mg twice a	
		IU/day			week to every day	
	King's college, London ⁽³⁾	1333-5000 IU/day	1000-3000 IU/day	15-150 U/kg/day	1 mg/day	
	Lane et al. (2)	5000-50000	1000-8000 IU/day	1 unit/kg/day	ORAL:2.5-5 mg	
		IU/day		,,	IM/SQ/IV: 1-10	
		-,,			mg/dose	
	Optimal approach	would be to adjust	t the doses based on targe	et serum levels. Refer t		
	Safety	5 a.a. 5 c t 5 d a j d 5 t			p	
	1 20.014					

ANMF consensus group JHCH_NICU_19.179

Vitamins in cholestasis

Newborn use only

	Excessive doses of vitamins can lead to adverse effects listed in adverse reactions. ⁽¹⁾
Practice points	Aim to maintain the normal range of serum vitamin A, E and D levels. Reference values may vary. Check with your local laboratory. Published recommendations of INR ≤1.2 is often not possible in practice despite high doses of vitamin K. Higher INR values are often accepted as long as there is no clinical evidence of coagulation dysfunction.
References	 Dani C, Pratesi S, Raimondi F, Romagnoli C. Italian guidelines for the management and treatment of neonatal cholestasis. Italian Journal of Pediatrics. 2015;41:1-12. Lane E, Murray KF. Neonatal cholestasis. Pediatric Clinics. 2017;64:621-39. Mancell S, Islam M, Dhawan A, Whelan K. Fat-soluble vitamin assessment, deficiency and supplementation in infants with cholestasis. Journal of Human Nutrition and Dietetics. 2022;35:273-9. Feldman AG, Sokol RJ. Neonatal cholestasis. Neoreviews. 2013;14(2):e63-e73. Feldman AG, Sokol RJ. Neonatal Cholestasis: Updates on Diagnostics, Therapeutics, and Prevention. NeoReviews. 2021;22:e819-e36.

VERSION/NUMBER	DATE
Original 1.0	21/07/2022
Current 1.0(Minor errata)	10/08/2023
REVIEW	21/07/2027

Authors Contribution

Original author/s	Srinivas Bolisetty
Evidence Review	Srinivas Bolisetty, Kate Dehlsen
Expert review	Kate Dehlsen, Scott Nightingale, Michael Stormon, Usha Krishnan, Lizsa Tan, Katie Marks, Andrea Horvath
Nursing Review	Eszter Jozsa, Sarah Neale
Pharmacy Review	Mohammad Irfan Azeem, Thao Tran
ANMF Group contributors	Nilkant Phad, Bhavesh Mehta, John Sinn, Rebecca Barzegar, Kate Dehlsen, Helen Huynh, Michelle Jenkins, Stephanie Halena, Renae Gengaroli
Final editing	Thao Tran
Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty